vs

Side-by-side financial comparison of PARKE BANCORP, INC. (PKBK) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $22.7M, roughly 1.6× PARKE BANCORP, INC.). PARKE BANCORP, INC. runs the higher net margin — 48.8% vs -304.2%, a 353.0% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 35.7%). PARKE BANCORP, INC. produced more free cash flow last quarter ($39.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 22.6%).

Parke Bancorp, Inc. is a U.S. regional bank holding company operating Parke Bank. It offers commercial and retail banking services including deposit products, mortgage loans, small business financing and personal lending, primarily serving customers across New Jersey and the Philadelphia metropolitan area.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

PKBK vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.6× larger
RXRX
$35.5M
$22.7M
PKBK
Growing faster (revenue YoY)
RXRX
RXRX
+646.1% gap
RXRX
681.7%
35.7%
PKBK
Higher net margin
PKBK
PKBK
353.0% more per $
PKBK
48.8%
-304.2%
RXRX
More free cash flow
PKBK
PKBK
$86.3M more FCF
PKBK
$39.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
22.6%
PKBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PKBK
PKBK
RXRX
RXRX
Revenue
$22.7M
$35.5M
Net Profit
$11.1M
$-108.1M
Gross Margin
59.8%
Operating Margin
64.2%
-304.8%
Net Margin
48.8%
-304.2%
Revenue YoY
35.7%
681.7%
Net Profit YoY
49.8%
39.6%
EPS (diluted)
$0.93
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PKBK
PKBK
RXRX
RXRX
Q4 25
$22.7M
$35.5M
Q3 25
$21.0M
$5.2M
Q2 25
$18.7M
$19.2M
Q1 25
$17.4M
$14.7M
Q4 24
$16.8M
$4.5M
Q3 24
$15.6M
$26.1M
Q2 24
$15.5M
$14.4M
Q1 24
$15.1M
$13.8M
Net Profit
PKBK
PKBK
RXRX
RXRX
Q4 25
$11.1M
$-108.1M
Q3 25
$10.6M
$-162.3M
Q2 25
$8.3M
$-171.9M
Q1 25
$7.8M
$-202.5M
Q4 24
$7.4M
$-178.9M
Q3 24
$7.5M
$-95.8M
Q2 24
$6.5M
$-97.5M
Q1 24
$6.2M
$-91.4M
Gross Margin
PKBK
PKBK
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
PKBK
PKBK
RXRX
RXRX
Q4 25
64.2%
-304.8%
Q3 25
64.2%
-3327.6%
Q2 25
59.0%
-916.8%
Q1 25
59.1%
-1297.9%
Q4 24
58.0%
-4042.4%
Q3 24
60.2%
-377.1%
Q2 24
56.7%
-697.4%
Q1 24
55.4%
-698.4%
Net Margin
PKBK
PKBK
RXRX
RXRX
Q4 25
48.8%
-304.2%
Q3 25
50.6%
-3135.3%
Q2 25
44.3%
-894.2%
Q1 25
44.6%
-1373.3%
Q4 24
44.2%
-3935.5%
Q3 24
48.1%
-367.5%
Q2 24
41.6%
-676.6%
Q1 24
40.7%
-662.4%
EPS (diluted)
PKBK
PKBK
RXRX
RXRX
Q4 25
$0.93
$-0.17
Q3 25
$0.89
$-0.36
Q2 25
$0.69
$-0.41
Q1 25
$0.65
$-0.50
Q4 24
$0.61
$-0.56
Q3 24
$0.62
$-0.34
Q2 24
$0.53
$-0.40
Q1 24
$0.51
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PKBK
PKBK
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$324.5M
$1.1B
Total Assets
$2.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PKBK
PKBK
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
PKBK
PKBK
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
PKBK
PKBK
RXRX
RXRX
Q4 25
$324.5M
$1.1B
Q3 25
$314.8M
$1.0B
Q2 25
$312.2M
$919.1M
Q1 25
$305.9M
$933.9M
Q4 24
$300.1M
$1.0B
Q3 24
$296.5M
$524.6M
Q2 24
$292.8M
$584.4M
Q1 24
$288.4M
$401.2M
Total Assets
PKBK
PKBK
RXRX
RXRX
Q4 25
$2.2B
$1.5B
Q3 25
$2.2B
$1.4B
Q2 25
$2.2B
$1.3B
Q1 25
$2.1B
$1.3B
Q4 24
$2.1B
$1.4B
Q3 24
$2.1B
$726.5M
Q2 24
$2.0B
$775.9M
Q1 24
$2.0B
$557.8M
Debt / Equity
PKBK
PKBK
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PKBK
PKBK
RXRX
RXRX
Operating Cash FlowLast quarter
$39.6M
$-46.1M
Free Cash FlowOCF − Capex
$39.0M
$-47.3M
FCF MarginFCF / Revenue
171.3%
-133.1%
Capex IntensityCapex / Revenue
2.6%
3.5%
Cash ConversionOCF / Net Profit
3.57×
TTM Free Cash FlowTrailing 4 quarters
$63.5M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PKBK
PKBK
RXRX
RXRX
Q4 25
$39.6M
$-46.1M
Q3 25
$11.4M
$-117.4M
Q2 25
$6.8M
$-76.4M
Q1 25
$7.0M
$-132.0M
Q4 24
$35.2M
$-115.4M
Q3 24
$9.4M
$-59.2M
Q2 24
$8.9M
$-82.2M
Q1 24
$8.3M
$-102.3M
Free Cash Flow
PKBK
PKBK
RXRX
RXRX
Q4 25
$39.0M
$-47.3M
Q3 25
$11.2M
$-117.6M
Q2 25
$6.7M
$-79.6M
Q1 25
$6.6M
$-133.8M
Q4 24
$35.0M
$-116.7M
Q3 24
$9.4M
$-63.8M
Q2 24
$8.9M
$-83.4M
Q1 24
$8.3M
$-109.0M
FCF Margin
PKBK
PKBK
RXRX
RXRX
Q4 25
171.3%
-133.1%
Q3 25
53.5%
-2272.5%
Q2 25
35.8%
-413.9%
Q1 25
38.0%
-907.4%
Q4 24
209.1%
-2567.7%
Q3 24
60.0%
-244.6%
Q2 24
57.1%
-578.5%
Q1 24
55.1%
-789.9%
Capex Intensity
PKBK
PKBK
RXRX
RXRX
Q4 25
2.6%
3.5%
Q3 25
0.5%
4.7%
Q2 25
0.3%
16.4%
Q1 25
2.2%
12.4%
Q4 24
0.7%
28.6%
Q3 24
0.1%
17.5%
Q2 24
0.2%
8.2%
Q1 24
0.1%
48.2%
Cash Conversion
PKBK
PKBK
RXRX
RXRX
Q4 25
3.57×
Q3 25
1.07×
Q2 25
0.82×
Q1 25
0.90×
Q4 24
4.75×
Q3 24
1.25×
Q2 24
1.38×
Q1 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons